Holen Sie sich die Stockscreener-App
0.65
1.06%
0.0068
Handel nachbörslich:
.65
Schlusskurs vom Vortag:
$0.6432
Offen:
$0.675
24-Stunden-Volumen:
40,566
Relative Volume:
0.06
Marktkapitalisierung:
$15.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.19%
1M Leistung:
-0.03%
6M Leistung:
-67.98%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.64
$0.675
1-Wochen-Bereich:
$0.63
$0.699
52-Wochen-Spanne:
$0.63
$2.75
Metavia Inc Stock (MTVA) Company Profile
Firmenname
Metavia Inc
Sektor
Branche
Telefon
(857) 702-9600
Adresse
545 CONCORD AVENUE, CAMBRIDGE
Vergleichen Sie MTVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
0.65 | 15.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
Metavia Inc Aktie (MTVA) Neueste Nachrichten
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewswire
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - Eastern Progress
MetaVia Sees Obesity Opportunities Despite Challenging US Market - insights.citeline.com
MTVA stock touches 52-week low at $0.64 amid market challenges By Investing.com - Investing.com South Africa
MetaVia Inc. receives Nasdaq non-compliance notice - Investing.com Australia
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price - TipRanks
MTVA stock touches 52-week low at $0.64 amid market challenges - Investing.com Nigeria
MetaVia Reports Progress in Obesity and MASH Treatments - TipRanks
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study… - Zacks Small Cap Research
MetaVia Updates Corporate Presentation on DA-1726 Progress - TipRanks
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream - GlobeNewswire
Major Investment Alert: DONG-A ST CO., LTD Boosts Stake in MetaVia! - TipRanks
MetaVia (NASDAQ:MTVA) Price Target Lowered to $3.00 at Maxim Group - Defense World
Maxim Group Lowers MetaVia (MTVA) Price Target to $3.00 | MTVA S - GuruFocus
MetaVia price target lowered to $3 from $6 at Maxim - TipRanks
MetaVia (MTVA) Price Target Cut as Analyst Highlights Future Pro - GuruFocus
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - WV News
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - Stock Titan
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - The Malaysian Reserve
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promis - GuruFocus
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
Finanzdaten der Metavia Inc-Aktie (MTVA)
Es liegen keine Finanzdaten für Metavia Inc (MTVA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Metavia Inc-Aktie (MTVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | 10% Owner |
May 08 '25 |
Buy |
0.71 |
4,647,887 |
3,300,000 |
9,995,679 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):